Compare INBK & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INBK | HELP |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | Canada |
| Employees | 355 | 50 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.3M | 214.5M |
| IPO Year | N/A | N/A |
| Metric | INBK | HELP |
|---|---|---|
| Price | $25.64 | $4.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $23.25 | ★ $51.50 |
| AVG Volume (30 Days) | 33.3K | ★ 602.3K |
| Earning Date | 04-30-2026 | 07-01-2026 |
| Dividend Yield | ★ 1.06% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $279.34 | N/A |
| Revenue Next Year | $12.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.05 | $3.76 |
| 52 Week High | $28.51 | $8.55 |
| Indicator | INBK | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 59.63 | 44.48 |
| Support Level | $23.14 | $4.22 |
| Resistance Level | N/A | $4.75 |
| Average True Range (ATR) | 0.94 | 0.27 |
| MACD | 0.12 | 0.02 |
| Stochastic Oscillator | 74.44 | 50.51 |
First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking or treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.